PRELIMINARY DATA OF CPX-351 TREATMENT IN A MULTI-CENTER REAL-LIFE EXPERIENCE IN YOUNG PATIENTS (<60 YEARS OLD) AFFECTED BY THERAPHY RELATED ACUTE MYELOID LEUKEMIA AND ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED CHANGES

被引：0
|
作者：
Garibaldi, B. [1 ]
Brunetti, L. [2 ]
Vigna, E. [3 ]
Mauro, E. [4 ]
Maugeri, C. [4 ]
Parisi, M. S. [4 ]
Fiumara, P. F. [4 ]
Duminuco, A. [1 ]
Martino, E. [3 ]
Mazzantini, E. [5 ]
Galimberti, S. [5 ]
Gentile, M. [3 ]
Palumbo, G. A. [1 ,6 ]
Di Raimondo, F. [4 ,7 ]
Vetro, C.
机构：
[1] Univ Catania, Scuola Specializzaz Ematol, Catania, Italy
[2] Osped S Maria Misericordia, Div Ematol, Emilia Romagna, Italy
[3] Unita Enatol AO Cosenza, Cosenza, Italy
[4] AOU Policlin G Rodolico S Marco, Div Ematol, Catania, Italy
[5] Univ Pisa, UO Ematol, AOU Pisana, Pisa, Italy
[6] Univ Catania, Dipartimento Sci Med Chirurg & Technol Avanzate G, Catania, Italy
[7] Univ Catania, Dipartimento Chirurg Generale & Specialita Med Ch, Catania, Italy
来源：
HAEMATOLOGICA | 2021年 / 106卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
D058
引用
收藏
页码：133 / 134
页数：2
相关论文
共 50 条
  • [1] EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes
    Tzogani, Kyriaki
    Penttila, Karri
    Lapvetelainen, Tuomo
    Hemmings, Robert
    Koenig, Janet
    Freire, Joao
    Marcia, Silva
    Cole, Susan
    Coppola, Paola
    Flores, Beatriz
    Barbachano, Yolanda
    Roige, Silvia Domingo
    Pignatti, Francesco
    [J]. ONCOLOGIST, 2020, 25 (09): : E1414 - E1420
  • [2] Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia
    Przespolewski, Amanda
    Goldberg, Aaron D.
    Talati, Chetasi
    Fazal, Salman
    Vachhani, Pankit
    Sanikommu, Srinivasa R.
    Thota, Swapna
    Waksal, Julian
    Ball, Brian
    Famulare, Christopher
    Stahl, Maximilian
    Baron, Jeffrey
    Griffiths, Elizabeth A.
    Thompson, James E.
    Sweet, Kendra
    Wang, Eunice S.
    [J]. BLOOD, 2023, 141 (12) : 1489 - 1493
  • [3] Comparison of Hospital Length of Stay and Supportive Care Utilization Between Patients Treated with CPX-351 and 7+3 for Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes
    Price, Kwanza
    Cao, Zhun
    Lipkin, Craig
    Profant, Deb
    Robinson, Scott
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2022, 14 : 21 - 34
  • [4] Safety and efficacy of CPX-351 in younger patients &lt; 60 years old with secondary acute myeloid leukemia:An updated analysis
    Przespolewski, Amanda Cecile
    Talati, Chetasi
    Fazal, Salman
    Vachhani, Pankit
    Sanikommu, Srinivasa
    Thota, Swapna
    Baron, Jeffrey
    Griffiths, Elizabeth A.
    Thompson, James E.
    Sweet, Kendra Lynn
    Wang, Eunice S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Budget Impact Analysis of CPX-351 in the Treatment of Patients with Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC) from a US Payer Perspective
    Jensen, Ivar S.
    Wu, Elizabeth
    Sacks, Naomi
    Cyr, Philip
    Chung, Karen
    [J]. BLOOD, 2017, 130
  • [6] The UK Real-world Experience of CPX-351 for the Treatment of Therapy-related Acute Myeloid Leukaemia and Acute Myeloid Leukaemia with Myelodysplasia-related Changes: CREST Retrospective Clinical Trial Design
    Mehta, Priyanka
    Medalla, Greg
    Kuter, Hayley
    Legg, Alex
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 172 - 173
  • [7] Safety and Efficacy of Liposomal Cytarabine/Daunorubicin (CPX-351) in Younger Patients &lt; 60 Years Old with Secondary Acute Myeloid Leukemia
    Przespolewski, Amanda
    Talati, Chetasi
    Vachhani, Pankit
    Sanikommu, Srinivasa Reddy
    Thota, Swapna
    Baron, Jeffrey
    Griffiths, Elizabeth A.
    Thompson, James E.
    Sweet, Kendra L.
    Wang, Eunice S.
    [J]. BLOOD, 2018, 132
  • [8] CPX-351 FOR THE TREATMENT OF NEWLY DIAGNOSED, THERAPY-RELATED ACUTE MYELOID LEUKEMIA (TAML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC): AN ANALYSIS OF CLINICAL BENEFIT
    Chung, K. C.
    Ryan, R. J.
    Louie, A. C.
    [J]. VALUE IN HEALTH, 2018, 21 : S15 - S15
  • [9] Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
    Christina Rautenberg
    Friedrich Stölzel
    Christoph Röllig
    Matthias Stelljes
    Verena Gaidzik
    Michael Lauseker
    Oliver Kriege
    Mareike Verbeek
    Julia Marie Unglaub
    Felicitas Thol
    Stefan W. Krause
    Mathias Hänel
    Charlotte Neuerburg
    Vladan Vucinic
    Christian-Friedrich Jehn
    Julia Severmann
    Maxi Wass
    Lars Fransecky
    Jens Chemnitz
    Udo Holtick
    Kerstin Schäfer-Eckart
    Josephine Schröder
    Sabrina Kraus
    William Krüger
    Ulrich Kaiser
    Sebastian Scholl
    Kathrin Koch
    Lea Henning
    Guido Kobbe
    Rainer Haas
    Nael Alakel
    Maximilian-Alexander Röhnert
    Katja Sockel
    Maher Hanoun
    Uwe Platzbecker
    Tobias A. W. Holderried
    Anke Morgner
    Michael Heuser
    Tim Sauer
    Katharina S. Götze
    Eva Wagner-Drouet
    Konstanze Döhner
    Hartmut Döhner
    Christoph Schliemann
    Johannes Schetelig
    Martin Bornhäuser
    Ulrich Germing
    Thomas Schroeder
    Jan Moritz Middeke
    [J]. Blood Cancer Journal, 11
  • [10] CPX-351 Exposure-Response Based on Cumulative Dose of Cytarabine and Daunorubicin in Patients with Newly Diagnosed, Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes
    Banerjee, Kamalika
    Wang, Qi
    Wang, Jing
    Gibbons, Jackie
    [J]. BLOOD, 2017, 130
12345